Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

BAROSTIM THERAPY ™ in Heart Failure With Preserved Ejection Fraction: A Post-Market Registry With the CE-Marked BAROSTIM NEO™ System

NCT02876042 is registered in ClinicalTrials.gov with CVRx, Inc. as lead sponsor.

NCT NCT02876042
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02876042 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
BAROSTIM THERAPY ™ in Heart Failure With Preserved Ejection Fraction: A Post-Market Registry With the CE-Marked BAROSTIM NEO™ System
Lead sponsor
CVRx, Inc.
Phase
Observational
Overall status
Completed
Start date
March 23, 2017
Completion date
November 3, 2025
Enrollment
11 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

heart failure